Johnson & Johnson Announces Agreement to Acquire Alios BioPharma
News Oct 08, 2014
Johnson & Johnson has announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.
The acquisition will include Alios BioPharma’s portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV).
“We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy,” said William N. Hait, M.D., Ph.D., Global Head, Research & Development, Janssen Pharmaceutical Companies of Johnson & Johnson. “AL-8176 complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five.”
The closing is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The transaction is expected to close during the fourth quarter of 2014.
“Alios BioPharma’s pipeline is closely aligned with our vision to continue to address important unmet medical needs through scientific innovation,” said Johan Van Hoof, M.D., Global Head, Infectious Diseases and Vaccines, Janssen. “This acquisition will allow us to combine their innovative compounds with our vast experience in viral diseases to deliver novel medicines and treatment options for patients worldwide.”
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE